Methicillin-resistant Staphylococcus aureus (MRSA) is an isolate of Staphylococcus aureus that has genetic resistance to beta-lactam antibiotics, including methicillin, amoxicillin, and penicillin. This organism causes a variety of infections, ranging from mild skin infections to severe systemic conditions such as bacteremia, pneumonia, and endocarditis. A key feature of MRSA is its ability to survive antibacterial therapy, making it very difficult to treat. MRSA infections typically affect hospitalized patients or those who are immunocompromised, although a significant increase in MRSA-associated infections has been reported in recent years. Importantly, antibiotic resistance is a serious public health problem that requires appropriate management and treatment strategies.
History of the disease and interesting historical facts
MRSA was first identified in 1961 in the UK, just a few years after the introduction of methicillin into clinical practice. Since then, it has become one of the leading antibiotic-resistant staphylococcal pathogens. In the 1980s, an increase in MRSA cases in hospitals prompted research into understanding the mechanisms of its resistance and spread. In parallel, an increase in MRSA cases among healthy individuals in the community was observed. In the 1990s, the first case of community-associated MRSA was described, signaling the need for new diagnostic and treatment strategies for this infectious process.
Epidemiology
According to the U.S. Centers for Disease Control and Prevention (CDC), MRSA infections have been on the rise in both healthcare settings and the community in recent decades. In 2019, more than 100,000 cases of MRSA-related infections were reported in the U.S. About 20% of these cases were due to infections that occurred outside the hospital environment. Data analysis has shown that 30-50% people may be asymptomatic carriers of MRSA, facilitating its spread. Geographic variations in MRSA prevalence are also significant, making it difficult to adopt universal preventive measures.
Genetic predisposition to this disease
Genetic predisposition to MRSA infections is associated with a number of factors, including alleles of certain genes involved in the body's immune response. Studies show that mutations in genes encoding components of the immune system (e.g., IL-6, TNF-α) can increase the risk of developing severe infections. In addition, the presence of specific genes responsible for antibiotic resistance (e.g., mecA) is associated with MRSA resistance to beta-lactam drugs. Associations with genes responsible for cell membrane structure and metabolism have also been identified, which may also be the cause of predisposition to this disease.
Risk factors for the development of this disease
Risk factors that contribute to MRSA infections include:
- The presence of open wound surfaces or extensive burns.
- Long stay in hospital or intensive care.
- Use of invasive medical devices (catheters, breathing tubes).
- Long-term use of antibiotics, which can disrupt normal microflora.
- The presence of comorbidities such as diabetes or HIV.
- Contact with people who have active MRSA infections.
- Living conditions in overcrowded environments (e.g. prisons, military camps).
Each of these factors increases the likelihood of infection and the development of clinically significant disease.
Diagnosis of this disease
Diagnosis of MRSA includes several stages and methods:
- Main symptoms: skin infections such as boils and carbuncles, abscesses, pneumonia, urinary tract infections.
- Laboratory tests: microbiological culture of bacteria from the infectious site on nutrient media followed by testing for antibiotic resistance.
- Radiological examinations: chest x-ray to evaluate lung infections.
- Other types of diagnostics: PCR diagnostics, which allows for the rapid detection of the presence of resistance genes.
- Differential diagnosis: the presence of other staphylococcal infections and various pathogens such as Streptococcus pneumoniae or Pseudomonas aeruginosa is taken into account.
Correct diagnosis is critical to determining treatment strategy.
Treatment
Treatment of MRSA infections should be comprehensive and include several approaches:
- General treatment: assessment of the patient's condition, supportive therapy, including adequate fluid and electrolyte intake.
- Pharmacological treatment: use of antibiotics such as vancomycin, deptapeptide or linezolid, which are effective against MRSA.
- Surgical treatment: drainage of abscesses or removal of necrotic tissue in case of severe infections.
- Other treatments: The use of new antibiotics in clinical trials and alternative methods such as phage therapy may be considered.
Monitoring the response to treatment and adjusting therapy are important for a successful outcome.
List of medications used to treat this disease
The most common antibiotics used to treat MRSA include:
- Vancomycin
- Deptapeptide
- Linezolid
- Tigecycline
- Sedakan (Ceftaroline)
- Hemisulfan (Daptomycin)
Careful selection of antibiotic therapy is based on the results of microbiological examination and clinical effectiveness.
Disease monitoring
Monitoring for MRSA infection includes:
- Control stages: regular examinations and assessment of the patient’s clinical condition.
- Prognosis: Early diagnosis and adequate treatment usually provide a positive prognosis.
- Complications: relapse of infection, sepsis, or development of systemic infections are possible, so timely correction of therapy is critical.
Monitoring of patients with MRSA is essential to prevent serious consequences.
Age-related features of the disease
MRSA infections may present differently in different age groups:
- In neonates: high risk of colonization and infection, especially in premature infants.
- In children: Often presents as a skin infection or pneumonia.
- In adults, more severe forms of infection usually occur, including osteomyelitis and endocarditis.
- In older adults: Increased risk of serious infections due to multiple underlying medical conditions and decreased immune function.
In each of these cases, the specific clinical picture and treatment approaches should be taken into account.
Questions and Answers
- What is MRSA? MRSA stands for methicillin-resistant Staphylococcus aureus, a bacteria that causes infections and is resistant to standard beta-lactam antibiotics.
- What are the symptoms of MRSA infection? Symptoms may include redness, swelling, pain at the site of infection, as well as fever and general malaise in more serious infections.
- How to diagnose MRSA? Diagnosis includes microbiological examination, culture from the infectious site and PCR to detect resistance genes.
- How is MRSA treated? Treatment involves the use of specialized antibiotics such as vancomycin and surgery to drain abscesses if necessary.
- What are the risk factors for MRSA? Risk factors include open wounds, prolonged hospitalization, underlying medical conditions, and exposure to infected people.
A systematic approach to diagnosis, treatment and monitoring of MRSA infections will reduce morbidity and improve patient outcomes.
